Please login to the form below

Not currently logged in
Email:
Password:

Makena

This page shows the latest Makena news and features for those working in and with pharma, biotech and healthcare.

Overcoming quantitative pricing limitations

Overcoming quantitative pricing limitations

wrong. For example, in 2011, a company called KV Pharmaceuticals received orphan drugs status - and seven years of market exclusivity - for Makena, its own version of progesterone, used to reduce the ... The company set a price of $1, 500 per dose for

Latest news

  • Amag buys into maternal health business Amag buys into maternal health business

    Amag's primary objective in buying Lumara - which until this year was known as KV Pharmaceutical - is to gain ownership of Makena (hydroxyprogesterone caproate), a drug used in the management of ... The buoyant growth for Makena has come despite

  • March of Dimes cuts ties with KV Pharma

    in protest over the company's pricing for Makena (hydroxyprogesterone caproate injection), a drug to prevent preterm birth that won US Food and Drug Administration (FDA) approval in February. ... Makena, which was formerly known as Gestiva, was developed

  • K-V preterm birth drug approved

    Thirty-seven per cent of women treated with Makena delivered before 37 weeks, compared with 55 per cent of women in the control group. ... An international trial is ongoing to determine whether Makena reduces the number of babies who do not survive or

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2014 Pharma deals during September 2014

    KV Pharmaceuticals emerged from Chapter 11 bankruptcy in September 2013 with the new name Lumara Health and two divisions: maternal health for the orphan drug Makena; and women's health for ... The potential maximum sales multiple of 9 for Makena

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    Maternal health business including orphan drug to reduce risk of preterm birth Makena.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • KV Pharmaceutical names Joseph Mahady as chair KV Pharmaceutical names Joseph Mahady as chair

    This financial state was due to the flawed launch of its drug Makena to prevent premature birth. ... The company seems to be back on track, however, after reaching a settlement with Hologic, the original developers of Makena who sold the rights to KV.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics